Exosome-mediated transfer of circ_0063526 enhances cisplatin resistance in gastric cancer cells via regulating miR-449a/SHMT2 axis
- PMID: 36206102
- DOI: 10.1097/CAD.0000000000001386
Exosome-mediated transfer of circ_0063526 enhances cisplatin resistance in gastric cancer cells via regulating miR-449a/SHMT2 axis
Abstract
Exosomes are critical mediators of intercellular communication. Exosomal circular RNAs (circRNAs) have been reported to play critical roles in the development of chemoresistance in various tumors, including gastric cancer. However, the role of exosomal circ_0063526 in cisplatin (CDDP) resistance of gastric cancer is still unclear. The expression of circ_0063526, microRNA-449a (miR-449a) and serine hydroxymethyltransferase 2 (SHMT2) mRNA was determined by quantitative real-time PCR (qRT-PCR). Cell viability was assessed by the Cell Counting Kit-8 assay. Cell migration and invasion were evaluated by the transwell assay and wound healing assay. Western blot assay was used to measure the protein expression of light Chain 3 (LC3) I/II, p62 and SHMT2. Exosomes were detected using transmission electron microscopy. The size distribution of exosomes was analyzed by nanoparticle tracking analysis. The interaction between miR-449a and circ_0063526 or SHMT2 was confirmed by a dual-luciferase reporter and RNA pull-down assays. Circ_0063526 expression was increased in gastric cancer tissues and cells and CDDP-resistant cells. Extracellular circ_0063526 could be packaged into exosomes and transmitted to sensitive cells, thus disseminating CDDP resistance. Knockdown of exosomal circ_0063526 inhibited CDDP resistance via suppressing migration, invasion and autophagy in gastric cancer cells. Moreover, circ_0063526 was identified as a molecular sponge of miR-449a to upregulate SHMT2 expression. Further, exosomal circ_0063526 regulated SHMT2 expression to enhance CDDP resistance of gastric cancer cells. Additionally, high expression of exosomal circ_0063526 in serum was associated with poor response to CDDP treatment in gastric cancer patients. Exosomal circ_0063526 facilitated CDDP resistance in gastric cancer via regulating the miR-449a/SHMT2 axis.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.Mol Cell Biochem. 2021 Jun;476(6):2253-2267. doi: 10.1007/s11010-021-04083-8. Epub 2021 Feb 11. Mol Cell Biochem. 2021. PMID: 33570734
-
Circular RNA circ_0001017 Sensitizes Cisplatin-Resistant Gastric Cancer Cells to Chemotherapy by the miR-543/PHLPP2 Axis.Biochem Genet. 2022 Apr;60(2):558-575. doi: 10.1007/s10528-021-10110-6. Epub 2021 Jul 27. Biochem Genet. 2022. PMID: 34313883
-
Exosome-Mediated Transfer of circ_0000338 Enhances 5-Fluorouracil Resistance in Colorectal Cancer through Regulating MicroRNA 217 (miR-217) and miR-485-3p.Mol Cell Biol. 2021 Apr 22;41(5):e00517-20. doi: 10.1128/MCB.00517-20. Print 2021 Apr 22. Mol Cell Biol. 2021. PMID: 33722958 Free PMC article.
-
New insights into the potential of exosomal circular RNAs in mediating cancer chemotherapy resistance and their clinical applications.Biomed Pharmacother. 2024 Aug;177:117027. doi: 10.1016/j.biopha.2024.117027. Epub 2024 Jun 25. Biomed Pharmacother. 2024. PMID: 38925018 Review.
-
Roles of exosomal circRNAs in tumour immunity and cancer progression.Cell Death Dis. 2022 Jun 9;13(6):539. doi: 10.1038/s41419-022-04949-9. Cell Death Dis. 2022. PMID: 35676257 Free PMC article. Review.
Cited by
-
Harnessing the potential of small extracellular vesicle biomarkers for cancer diagnosis and prognosis with advanced analytical technologies.J Transl Int Med. 2025 Jun 20;13(3):187-200. doi: 10.1515/jtim-2025-0019. eCollection 2025 Jun. J Transl Int Med. 2025. PMID: 40896292 Free PMC article.
-
Exosomes: Diagnostic and Therapeutic Implications in Cancer.Pharmaceutics. 2023 May 11;15(5):1465. doi: 10.3390/pharmaceutics15051465. Pharmaceutics. 2023. PMID: 37242707 Free PMC article. Review.
-
Exosomes: their role and therapeutic potential in overcoming drug resistance of gastrointestinal cancers.Front Oncol. 2025 May 13;15:1540643. doi: 10.3389/fonc.2025.1540643. eCollection 2025. Front Oncol. 2025. PMID: 40432919 Free PMC article. Review.
-
Exosomal circRNAs in gastrointestinal cancer: Role in occurrence, development, diagnosis and clinical application (Review).Oncol Rep. 2024 Feb;51(2):19. doi: 10.3892/or.2023.8678. Epub 2023 Dec 15. Oncol Rep. 2024. PMID: 38099408 Free PMC article. Review.
-
Extracellular vesicle-delivered hsa_circ_0090081 regulated by EIF4A3 enhances gastric cancer tumorigenesis.Cell Div. 2024 Jun 11;19(1):19. doi: 10.1186/s13008-024-00123-z. Cell Div. 2024. PMID: 38862985 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
-
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al.; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385:977–1010.
-
- Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215–221.
-
- Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869–1883.
-
- Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 2016; 106:27–36.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical